Kiora Pharmaceuticals, Inc.
$2.52
▼
-0.51%
2026-04-21 07:45:02
www.kiorapharma.com
NCM: KPRX
Explore Kiora Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$9.96 M
Current Price
$2.52
52W High / Low
$4.18 / $1.76
Stock P/E
—
Book Value
$4.29
Dividend Yield
—
ROCE
-45.87%
ROE
-51.74%
Face Value
—
EPS
$-2.64
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
13
Beta
-0.77
Debt / Equity
2.28
Current Ratio
5.99
Quick Ratio
5.99
Forward P/E
-1.11
Price / Sales
—
Enterprise Value
$-6.96 M
EV / EBITDA
0.74
EV / Revenue
—
Rating
Buy
Target Price
$12
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Fennec Pharmaceuticals Inc. | $6.73 | — | $232.02 M | — | -10.57% | -65.82% | $9.92 / $5.02 | $1.04 |
| 2. | Nurix Therapeutics, Inc. | $17.04 | — | $1.81 B | — | -47.48% | -61.4% | $22.5 / $8.2 | $4.65 |
| 3. | Lisata Therapeutics, Inc. | $2.83 | — | $25.56 M | — | -124.1% | -75.53% | $5.07 / $1.81 | $1.68 |
| 4. | OKYO Pharma Limited | $1.59 | — | $85.27 M | — | 127.79% | 82.36% | $3.35 / $1.11 | $-0.09 |
| 5. | FibroBiologics, Inc. | $1.53 | — | $5.37 M | — | -211.82% | -4.19% | $30.6 / $1.03 | $1.85 |
| 6. | Larimar Therapeutics, Inc. | $4.81 | — | $499.68 M | — | -212.84% | -1.33% | $6.42 / $1.73 | $0.94 |
| 7. | Pharvaris N.V. | $28.97 | — | $1.86 B | — | -54.28% | -65.19% | $29.89 / $13.6 | $5.56 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.63 M | -2.52 M | -2.26 M | -2.06 M | -2.51 M | — |
| Net Profit | -6.52 M | 0.03 M | -2.15 M | -2.19 M | -4.22 M | — |
| EPS in Rs | -1.65 | 0.01 | -0.54 | -0.56 | -1.07 | -0.81 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 16 M | 0 M | 0 M |
| Operating Profit | -9.46 M | 5.58 M | -8.69 M | -11.73 M |
| Net Profit | -10.84 M | 3.59 M | -12.51 M | -13.58 M |
| EPS in Rs | -2.74 | 0.91 | -3.17 | -3.44 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 24.25 M | 36.48 M | 13.71 M | 18.68 M |
| Total Liabilities | 8.13 M | 10.72 M | 7.6 M | 7.27 M |
| Equity | 16.13 M | 25.76 M | 6.11 M | 11.41 M |
| Current Assets | 21.75 M | 29.71 M | 4.74 M | 7.68 M |
| Current Liabilities | 3.63 M | 6.01 M | 1.63 M | 3.27 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -9.96 M | 8.56 M | -9.56 M | -10.43 M |
| Investing CF | 14.43 M | -22.66 M | 0 M | 0.01 M |
| Financing CF | 0.27 M | 15.5 M | 5.97 M | 8.62 M |
| Free CF | -10.07 M | 8.55 M | -9.56 M | -10.43 M |
| Capex | -0.11 M | -0.01 M | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 128.73% | 7.88% | — | — |
| Profit Margin % | 22.47% | — | — | — |
| Operating Margin % | 34.88% | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | 35.63% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-06-11 | 1:0.111111 |
| 2022-09-27 | 1:0.025 |